zoledronic acid

(redirected from Reclast)
Also found in: Medical.
Related to Reclast: Zoledronic acid

zoledronic acid, zoledronate

n ácido zoledrónico, zoledronato (esp. Esp)
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Bisphosphonates, which include alendronate (Fosamax), risedronate (Actonel), zoledronic acid (Reclast), and ibandronate (Boniva) are recommended as the initial treatment.
Osteopenia treatment includes medications, which include bisphosphonate medications, such as ibandronate (Boniva), alendronate (Fosamax), risedronate (Actonel), zoledronate (Reclast) and raloxifene (Evista).
The most commonly used bisphosphonate was alendronate (Fosamax, Binosto), used by 72%, followed by zoledronic acid (Reclast, Zometa), used by 16%.
Bisphosphonate drugs, such as alendronate (Fosamax), ibandronate (Boniva) and zoledronic acid (Reclast), are proven to combat bone loss and fractures in people with the bone-thinning disease osteoporosis.
M2 PHARMA-June 5, 2017-Mylan introduces generic Reclast Injection for treating Paget's disease
M2 EQUITYBITES-June 5, 2017-Mylan introduces generic Reclast Injection for treating Paget's disease
Pharmacologic options to prevent subsequent fragility fractures include the bisphosphonates alendronate, risedronate, and zoledronic acid (Reclast), and also the monoclonal antibody denosumab (Prolia).
Table 1 First-Generation Drugs Second Generation Non-nitrogen containing BPs (NNBP) (Aminobisphosphonate Drugs) Nitrogen containing BPs (NBP) Bonefos (clodronate) Actonel (risedronate sodium) Relative potency of 10 PO and IV Relative potency of 5000 PO formulations Aredia (pamidronate disodium) Didronel (etidronate disodium) Relative potency 100 IV Relative potency of 1 PO Boniva (ibandronate sodium) Skelid (tiludronic disodium) Relative potency 10000 Relative potency of 10 PO PO and IV formulations Fosamax (alendronate sodium) Relative potency 1000 PO Reclast (zoledronic acid) Relative potency 100000 IV Formulation Infused annually for osteoporosis FDA approval pendin Zometa (zoledronic acid) Relative potency 100000 IV Table 2 Risk factors Literature Of Review 1.
Zoledronic acid (Reclast) is the most potent BP and is given by an IV infusion annually at a dose of 5 mg diluted in dextrose saline.